MONEY

Merck's KEYTRUDA ® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 00:00
Merck's KEYTRUDA ® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Read More

Tags:

Previous Article

Iran says it is open to talks but rejects pressure as US, EU impose sanctions

Next Article

Abbot Schröder elected Abbot Primate of Benedictine Confederation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Life Time to Host Complimentary GLP-1, Weight Loss Livestream Event with Chief Science Officer and Experts September 25

Life Time to Host Complimentary GLP-1, Weight Loss Live...

Tomas Kauer - Mode... Sep 24, 2024

London stocks edge lower ahead of PMI data

London stocks edge lower ahead of PMI data

Tomas Kauer - Mode... Sep 23, 2024

Orchestra BioMed director sells over $30k in company shares

Orchestra BioMed director sells over $30k in company sh...

Tomas Kauer - Mode... Sep 11, 2024